Page 137 - MemoriaBBN-Eng

www.ciber-bbn.es

• C i, e e, e o, C Jl, m m, P d .. Multifunctio-
Most relevant ABrerAlizondosteBAnorCheroelGAreJoulidoet Al
nal nanovesicle-bioactive conjugates prepared by a one-step scalable method using
scientific CO2-expanded solvents.Nano Lett. 2013 Aug 14;13(8):3766-74.

articles
• Gomes-dA-silvA lC, Fernández y, ABAsolo i, sChWArtz s Jr, rAmAlho Js, Pedroso de limA mC
et Al.. Efficient intracellular delivery of siRNA with a safe multitargeted lipid-based

nanoplatform.Nanomedicine (Lond). 2013 Sep;8(9):1397-413.

• CorChero Jl,. Unconventional microbial systems for the cost-efficient production of
high-quality protein therapeutics.Biotechnology advances. 2013;Número: 15 Volu-

me: 31 Issue: 2 Pages: (15, 31, 2):140-153 .

• FontrodonA l, PortA-de-lA-rivA m, morán t, niu W, díAz m, AristizáBAl-CorrAles d et
.. RSR-2, the Caenorhabditis elegans ortholog of human spliceosomal component
Al
SRm300/SRRM2, regulates development by influencing the transcriptional machi-
nery.PLoS Genet. 2013 Jun;9(6):e1003543.

• m r, r P, B s, d h, F Am, m-l s, A
AzzoliniodriGuesAzzoCCooPesoerreirAAteoozAnondrettA
e, Woerner sm, AlAzzouzi h, lAndolFi s, hernández-losA J, mACAyA i, suzuKi h, rAmón y

CAJAl s, mooseKer ms, mAriAdAson Jm, GeBert J, hoFstrA rm, reventós J, yAmAmoto h,
sChWArtz s Jr, ArAnGo d. Brush border myosin Ia inactivation in gastric but not en-
ó
dometrial tumors.International journal of cancer. Journal international du cancer.
2013;132(8):1790-9.

Highlights
The group on Drug Delivery and Targeting seeks two main goals; on the one
hand, the identification of new disease biomarkers and therapeutic targets, with

special focus on cancer, and on the other hand, the development of new drug
delivery and targeting approaches for clinical applications. Among our projects

are two ERANET projects focused in nanomedicine applications involving SME’s

in which animal models are being used for preclinical validation of new therapies
directed against tumor cells (IMMAPROT on Industrial biotechnology – ERA-IB;

NANOSTEM – EuroNanoMed, coordinated by him), and an international project of

the Iberian Nanotechnology Institute (OncoNanoTarget). Two additional projects
from Marat TV3 (focused in drug delivery systems for the Fabry disease) and

INNPACTO (also involving industry) were granted in 2013, and additional National
grants were also obtained. Several in vitro and in vivo cancer models have been

generated by the group for preclinical testing of nanomedicines, including the

generation of specific cancer stem cell models. Two patents from the group are
in National Fases and a new PCT has been issued on liposomal formulations. Dr

Schwartz Jr is also member of the Nanomedicine Spanish Platform (NanomedS-

pain), the “European Platform for Nanomedicine” and the “European Fundation
for Clinical Nanomedicine” (CLINAM), and also a core member of the Nanome-

dicine networks “NanoBioMed Catalunya” and “CONNECT-EU”. Dr Schwartz has
also been appointed as Scientific Advisor by the Southern Denmark University of 13
20
the excellence center NANOCAN for Nanomedicine. Further, Dr Schwartz’s group T
OR
published papers in top science journals in 2013. Dr Schwartz’s has been also P
nominated associate editor of Nanomedicine NMB (FI:6,9)
RE
L
A
NU
N
A
N /
B
-B
R
BE
CI

137